Clinical Trial

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-01-21 -> 2026-12-01 2026-05-08
minor Completion pushed: 2026-01-21 -> 2026-12-01 2026-05-08
Trial Details
NCT Number NCT05506943
Lead Sponsor Compass Therapeutics
Conditions Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
Enrollment 168 participants
Start Date 2023-01-09
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-07